Australia Approves MDMA and Psilocybin for Mental Health Treatment:
A Milestone for Psychedelic Research and Therapy

07. April 2023

Australia has become the first country to officially recognize the medicinal value of psychedelics, authorizing qualified psychiatrists to prescribe MDMA for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression starting from July 2023. This decision by the Therapeutic Goods Administration (TGA) has generated cautious optimism within the psychiatric community and the broader field of psychedelic research.

​

Dr. Matthias Grill, our CEO of MiHKAL, expressed his thoughts on Australia's decision:

"This milestone in Australia marks a significant turning point in the global perception and acceptance of psychedelics for therapeutic purposes. At MiHKAL, we absolutely believe in the potential of these substances to transform mental health care and improve the lives of countless individuals. We are inspired by Australia's pioneering efforts and hopeful that other countries will follow suit in recognizing the benefits of psychedelic-assisted therapies. We look forward to continuing our research and contributing to this evolving field, as we strive to develop novel and effective compounds to facilitate these treatments."

​

The decision made by Australia could have far-reaching implications for the field of psychedelic research. As more countries consider embracing the potential therapeutic value of psychedelics, opportunities for growth and innovation in this sector could expand significantly.

The global community of researchers, clinicians, and companies involved in psychedelic research, including MiHKAL GmbH, will be watching closely as Australia embarks on this new chapter. They will be eager to learn from the successes and challenges that arise from this decision to incorporate the potential of psychedelic-assisted therapies in addressing critical mental health issues.